CARSGEN-B Shares Climb Over 3% as EHA Congress Accepts Abstracts for CT0596 and CT1190B Studies

Stock News

May 06

CARSGEN-B (02171) rose more than 3%, with the stock up 3.13% to HK$21.76 at the time of writing. The trading volume was HK$7.9942 million.

Recently, CARSGEN-B announced that abstracts summarizing the results of Investigator-Initiated Trials for CT0596, a universal CAR-T cell product targeting BCMA for the treatment of relapsed/refractory multiple myeloma/plasma cell leukemia, and for CT1190B, a universal CAR-T cell product targeting CD19/CD20 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma, have been accepted for poster presentation at the 2026 European Hematology Association Annual Congress. The abstracts and further details will be released after 15:30 Central European Summer Time on May 12, 2026.

CT0596 is a universal CAR-T cell therapy targeting BCMA, developed on CARSGEN's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or PCL. The company plans to initiate a Phase Ib clinical trial for R/R MM and primary plasma cell leukemia in 2026. CT1190B is a universal CAR-T cell therapy targeting CD19/CD20, also developed on the THANK-u Plus™ platform. The company plans to commence a Phase Ib registration clinical trial for this product in R/R B-NHL in 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1163787408"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163787408\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163787408?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 09:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163787408","market":"us","top_or_hot":-1,"title":"CARSGEN-B Shares Climb Over 3% as EHA Congress Accepts Abstracts for CT0596 and CT1190B Studies","media":"Stock News","content":"<p>CARSGEN-B (02171) rose more than 3%, with the stock up 3.13% to HK$21.76 at the time of writing. The trading volume was HK$7.9942 million.</p>\n<p>Recently, CARSGEN-B announced that abstracts summarizing the results of Investigator-Initiated Trials for CT0596, a universal CAR-T cell product targeting BCMA for the treatment of relapsed/refractory multiple myeloma/plasma cell leukemia, and for CT1190B, a universal CAR-T cell product targeting CD19/CD20 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma, have been accepted for poster presentation at the 2026 European Hematology Association Annual Congress. The abstracts and further details will be released after 15:30 Central European Summer Time on May 12, 2026.</p>\n<p>CT0596 is a universal CAR-T cell therapy targeting BCMA, developed on CARSGEN's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or PCL. The company plans to initiate a Phase Ib clinical trial for R/R MM and primary plasma cell leukemia in 2026. CT1190B is a universal CAR-T cell therapy targeting CD19/CD20, also developed on the THANK-u Plus™ platform. The company plans to commence a Phase Ib registration clinical trial for this product in R/R B-NHL in 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARSGEN-B Shares Climb Over 3% as EHA Congress Accepts Abstracts for CT0596 and CT1190B Studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARSGEN-B Shares Climb Over 3% as EHA Congress Accepts Abstracts for CT0596 and CT1190B Studies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-06 09:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARSGEN-B (02171) rose more than 3%, with the stock up 3.13% to HK$21.76 at the time of writing. The trading volume was HK$7.9942 million.</p>\n<p>Recently, CARSGEN-B announced that abstracts summarizing the results of Investigator-Initiated Trials for CT0596, a universal CAR-T cell product targeting BCMA for the treatment of relapsed/refractory multiple myeloma/plasma cell leukemia, and for CT1190B, a universal CAR-T cell product targeting CD19/CD20 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma, have been accepted for poster presentation at the 2026 European Hematology Association Annual Congress. The abstracts and further details will be released after 15:30 Central European Summer Time on May 12, 2026.</p>\n<p>CT0596 is a universal CAR-T cell therapy targeting BCMA, developed on CARSGEN's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or PCL. The company plans to initiate a Phase Ib clinical trial for R/R MM and primary plasma cell leukemia in 2026. CT1190B is a universal CAR-T cell therapy targeting CD19/CD20, also developed on the THANK-u Plus™ platform. The company plans to commence a Phase Ib registration clinical trial for this product in R/R B-NHL in 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1163787408","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163787408","pubTimestamp":1778031862,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) rose more than 3%, with the stock up 3.13% to HK$21.76 at the time of writing. The trading volume was HK$7.9942 million. Recently, CARSGEN-B announced that abstracts summarizing the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK1587":"次新股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK1574":"生物医药B类股","02171":"科济药业-B","BK1585":"昨日强势股","VXUS":"国际股票ETF-Vanguard"},"translate_title":"随着EHA大会接受CT0596和CT1190B研究摘要，CARSGEN-B股价上涨超过3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1,"VXUS":1},"content_text":"CARSGEN-B (02171) rose more than 3%, with the stock up 3.13% to HK$21.76 at the time of writing. The trading volume was HK$7.9942 million.\nRecently, CARSGEN-B announced that abstracts summarizing the results of Investigator-Initiated Trials for CT0596, a universal CAR-T cell product targeting BCMA for the treatment of relapsed/refractory multiple myeloma/plasma cell leukemia, and for CT1190B, a universal CAR-T cell product targeting CD19/CD20 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma, have been accepted for poster presentation at the 2026 European Hematology Association Annual Congress. The abstracts and further details will be released after 15:30 Central European Summer Time on May 12, 2026.\nCT0596 is a universal CAR-T cell therapy targeting BCMA, developed on CARSGEN's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or PCL. The company plans to initiate a Phase Ib clinical trial for R/R MM and primary plasma cell leukemia in 2026. CT1190B is a universal CAR-T cell therapy targeting CD19/CD20, also developed on the THANK-u Plus™ platform. The company plans to commence a Phase Ib registration clinical trial for this product in R/R B-NHL in 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}